

<b>Reference:</b>	FOI.16819.25
<b>Subject:</b>	Immunoglobulin treatments
<b>Date of Request:</b>	11 March 2025

**Requested:**

In the past 3 months how many patients have received the following immunoglobulin treatments (for any disease):

- Cutaquig
- Cuvitru
- Gammagard
- Gammanorm
- Hizentra
- Hyqvia
- Intratect
- Iqymune
- Kiovig
- Privigen
- Octagam
- Panzyga
- Subgam
- Any other normal immunoglobulin

**Response:**

Hywel Dda University Health Board (UHB) provides within the table below, the number of patients that received the immunoglobulin treatments listed, for any condition, during the period 1 December 2024 to 28 February 2025.

Medication	Number
Cutaquig	0
Cuvitru	0
Gammagard	0
Gammanorm	0
Hizentra	0
Hyqvia	*
Intratect	0
Iqymune	*
Kiovig	0
Privigen	30
Octagam	*
Panzyga	0
Subgam	0
Any other normal immunoglobulin: Gamunex	8

Where the figures in the table have been replaced with an asterisk (\*), the UHB is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this

detail under Section 40(2) of the Freedom of Information Act 2000 (FOIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.